As part of an updated push to coordinate federal action to strengthen dementia care and research, the U.S. Department of Health and Human Services (HHS) ...

Missing your pills one morning is usually not a problem. But it is important to make a habit out of taking them on a daily basis.

In the last three years, the FDA has approved two disease-modifying drugs for those with early stage Alzheimer's disease. A ...

Tempus AI, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 08:30 AM Sep. 11 Tempus AI, Inc. Launches Effort To Build The Largest Multimodal Whole-Genome Dataset ...

RFK Jr. and Dr. Oz pitched a new Alzheimer's prevention plan in Fort Lauderdale, where nearly 14% of seniors already have the ...

Pathos AI, a clinical-stage AI and technology company advancing its own therapeutic pipeline, today announced multi-year strategic collaborations with Bristol Myers Squibb (NYSE: BMY, "BMS") and ...

Researchers want to shortcut a search that has moved painfully slowly for years, and they are starting with two surprisingly ...

The U.S. Department of Health and Human Services (HHS) today announced the 2026 Update to the National Plan to Address ...

Carrie Lee from the Alzheimer's Association and Nathan Richardson, a volunteer for the organization, joined News 9 to discuss ...

Medications commonly used to treat attention-deficit/hyperactivity disorder (ADHD) may help reduce certain symptoms of ...

The AD-SMART trial tests repurposed drugs like metformin and atomoxetine in a hopeful, faster approach to Alzheimer’s care.

Pathos AI announced multi-year strategic collaborations with Bristol Myers Squibb and Tempus AI, Inc. to build a specialized, curated dataset and agentic AI capabilities for Alzheimer?s disease and ...